Shift to single-dose HPV vaccine unlikely

A shift to a single-dose HPV vaccine program is unlikely despite a study showing it may be just as protective as the currently recommended three doses, according to an Australian HPV expert.

Dr Julia Brotherton, medical director of the National HPV Vaccination Program Register, says the findings from a trial of the bivalent HPV vaccine Cervarix could be a game changer for developing  countries but not for Australia.

The study, which combined results from about 25,000 women from a Costa Rican trial and the international PATRICIA trial, found that one dose of the HPV-16/18